Predictors of rTMS and Group Therapy Efficacy in Adolescent Depression
NCT ID: NCT07283419
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
163 participants
OBSERVATIONAL
2023-08-01
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EEG-Triggered rTMS and Group Therapy for Adolescents With Depression and Self-Harm
NCT07047534
Efficacy and Safety of Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study
NCT07185438
Influence of rTMS on Symptoms and Cognitive Function in Patients With Psychiatric Disorders
NCT04055181
Efficacy and Mechanism of rTMS on the Symptoms of Pleasure Deficit in Adolescent Depression
NCT06580249
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
NCT02213016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Baseline assessments included the Family Environment Scale (FES) and a neuropsychological battery including the Stroop Color-Word Test and Wisconsin Card Sorting Test (WCST). The primary outcome was the percentage reduction in depressive symptoms measured by the HAMD-24 scale. The study employs multiple linear regression to determine which baseline factors independently predict superior treatment outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rTMS + Group Therapy Cohort
Adolescents diagnosed with MDD who received the standardized combined intervention.
Repetitive Transcranial Magnetic Stimulation (rTMS)
High-frequency (10 Hz) rTMS applied over the left dorsolateral prefrontal cortex (DLPFC), administered 5 days per week for 4 weeks (20 sessions total).
Group Cognitive Behavioral Therapy (CBT)
Manualized group therapy sessions focused on psychoeducation, cognitive restructuring, emotion regulation, and interpersonal skills, held twice weekly for 4 weeks (8 sessions total).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive Transcranial Magnetic Stimulation (rTMS)
High-frequency (10 Hz) rTMS applied over the left dorsolateral prefrontal cortex (DLPFC), administered 5 days per week for 4 weeks (20 sessions total).
Group Cognitive Behavioral Therapy (CBT)
Manualized group therapy sessions focused on psychoeducation, cognitive restructuring, emotion regulation, and interpersonal skills, held twice weekly for 4 weeks (8 sessions total).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Score of ≥ 20 on the 24-item Hamilton Depression Rating Scale (HAMD-24).
* Sufficient intellectual and linguistic ability to complete assessments and participate in therapy.
* Provided written informed consent (participants and guardians).
Exclusion Criteria
* Current substance use disorder.
* Significant neurological illness (e.g., epilepsy) or metallic implants contraindicated for rTMS.
* Receiving concurrent formal psychotherapy outside the study protocol.
12 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Hospital of Hebei Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanju Liu
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023S00133
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.